Compare IBTA & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IBTA | SLBT |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.3M | 846.7M |
| IPO Year | 2024 | 2025 |
| Metric | IBTA | SLBT |
|---|---|---|
| Price | $48.46 | $1.31 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $36.57 | N/A |
| AVG Volume (30 Days) | ★ 226.5K | 70.1K |
| Earning Date | 11-02-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,389,000.00 | N/A |
| Revenue This Year | $3.20 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.10 | $1.31 |
| 52 Week High | $50.54 | $6.25 |
| Indicator | IBTA | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 70.26 | 24.11 |
| Support Level | $35.30 | N/A |
| Resistance Level | N/A | $1.75 |
| Average True Range (ATR) | 2.05 | 0.11 |
| MACD | 0.42 | 0.01 |
| Stochastic Oscillator | 79.28 | 0.00 |
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.